Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Interferon-α treatment in systemic mastocytosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Interferon alpha for treatment of chronic myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Interferon treatment in patients with hypereosinophilia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of the blood eosinophil count with end-organ symptoms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hydrochloric acid prolongs the lifetime of central venous catheters in haematologic patients with bacteraemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Patients with systemic mastocytosis are rare, constitute a heterogeneous clinical entity and some may not require treatment until long after diagnosis. However, most patients who present with disabling symptoms, organ involvement and fulfill B or C findings as outlined in the 2008 WHO classification need treatment. This review on interferon treatment in systemic mastocytosis documents an effect of this biological agent in some patients with mastocytosis. However, the place of interferon-α, as mono- or combination therapy, in the treatment algorithm may only be definitely established in multicenter studies, which are based on the principles of controlled clinical trials.
OriginalsprogEngelsk
TidsskriftCurrent Drug Targets
Vol/bind12
Udgave nummer3
Sider (fra-til)433-6
Antal sider4
ISSN1389-4501
StatusUdgivet - 1 mar. 2011

ID: 32236753